Marizyme, Inc.'s Krillase Therapeutic Platform Shows Wide Medical
Application and Treatment Potential -- Spotlight Growth
Sacramento, CA -- March 14, 2019 -- InvestorsHub NewsWire --
Spotlight Growth has published new content on Marizyme, Inc.
(“Marizyme” or the “Company”) (OTC Pink: MRZM), a
biotechnology company focused on its clinically-tested and patented
use of protease therapeutic platform called Krillase. Clinical
testing and research have shown Krillase to be a treatment for
acute ischemic stroke, myocardial infarction, deep-vein thrombosis,
wound/burn care, and more. Krillase is classified as a Class III
medical device in Europe for the treatment of chronic wounds.
The comprehensive report provides an overview
of Marizyme, the Krillase platform, latest
news, and management’s plans to continue growing the
company.
ResearchAndMarkets: Global Wound Care Market Estimated
Worth $42.07 Billion By 2024
The global population continues to age, as fewer people continue
to have children. According to the World Bank, the global
population aged 65 or older has grown from 4.97% in 1960 to an
estimated 8.70% in 2017. Aside from the aging population, global
society suffers from poor diet and increasingly sedentary
lifestyles. This has led to a worldwide increase in diseases such
as diabetes and obesity. These factors present a number of
challenges for society, particularly healthcare services and
technology to meet growing demand for care.
Wound care is another key market that will be in focus due to
aging populations and diseases facing the globe today. Chronic
wound care is already a multi-billion-dollar market and is forecast
to see continue growth.
According to ResearchAndMarkets.com, the global wound care
market is estimated to grow to $42.07 billion by 2024, which
represents a CAGR of 6.20% between 2018 and 2024. The market
research firm notes that an increasingly aged population, growth in
surgeries, and even increasing road accidents as major sources of
growth for the wound care market. ResearchAndMarkets.com sees the
United States as being one of the main drivers of growth, but the
market researchers also see strength from other parts of the
world.
Global Market Insights, Inc. estimates the global advanced
wound care market to reach $13 billion by 2024, which represents a
CAGR of 5.40%. The market research analysts estimate that North
America will continue to dominate the market through 2024. With
that said, other international markets are estimated to see faster
growth over the same time period.
According to the report, “Rising incidences chronic diseases and
consequent rise in number of patients with acute and chronic wounds
will escalate the market growth over forecast timeframe. Favorable
demographic trends such as increasing geriatric population and
lifestyle changes such as adoption of sedentary lifestyle will
further support rise in prevalence of chronic diseases. This is
expected to escalate the prevalence of wounds and associated cost
burden thereby augmenting demand for wound care
products.”
MRZM: Initial Krillase Application To Focus On Wound
Care and Thrombosis Markets
Marizyme, Inc.’s Krillase main active ingredient can only be
derived from Antarctic krill. The mix of proteinases and
peptidases helps the Antarctic krill digest and break down its food
in the extremely cold environment. As a result, the specialized
enzymes provide a “cutting” capability. Krillase has already been
classified as a Class III medical device in Europe for the
treatment of chronic wounds.
Currently, Marizyme has a product pipeline that seeks
to focus on developing products that treat the most expensive
conditions across the acute care market. Here is a breakdown of the
breakdown of the current pipeline and where it stands in
the clinical stages:
· MB101 – Therapy for
Complex Infected Wounds & Burns: Completed Phase 1
trials
· MB102 – Therapy
for Acute Ischemic Stroke: Nearing end of
pre-clinical stage
· MB103 – Therapy
for Ischemic Myocardial Infarcs: Halfway through
pre-clinical stage
· MB104 – Therapy
for Deep Vein Thrombosis: Early pre-clinical
stage
While these represent the first four focuses that Marizyme will
turn to, the company also plans to obtain additional funds over the
next five years to conduct necessary research, development, and
clinical testing on the Krillase platform to be a
potential treatment in the following markets:
-HIV/AIDS treatment: $20.45 billion market
-Herpes treatment: $1.8 billion market
-Oral mucositis treatment: $1 billion market
-Plaque removal: $500 million market
-Canker sore treatment: $400 million market
-Gingivitis treatment: $290.50 million market
For more information on Marizyme, please
visit: http://marizyme.com and http://spotlightgrowth.com/index.php/2019/03/12/spotlight-growth-report-marizyme-inc-otc-pink-mrzm/
SpotlightGrowth.com is a digital hub for micro-caps,
small-caps, venture capital, private equity, crowdfunding,
cryptocurrency, and other emerging growth
investors. SpotlightGrowth.com serves as our media
subsidiary and provides insights on small cap companies.
Disclaimer:
Spotlight Growth is compensated, either directly or via a third
party, to provide investor relations services for its
clients. Spotlight Growth creates exposure for companies
through a customized marketing strategy, including design of
promotional material, the drafting and editing of press releases
and media placement.
All information on featured companies is provided by the
companies profiled, or is available from public sources. Spotlight
Growth and its employees are not a Registered Investment Advisor,
Broker Dealer or a member of any association for other research
providers in any jurisdiction whatsoever and we are not qualified
to give financial advice. The information contained herein is based
on external sources that Spotlight Growth believes to be reliable,
but its accuracy is not guaranteed. Spotlight Growth may
create reports and content that has been compensated by a company
or third-parties, or for purposes of self-marketing. Spotlight
Growth was compensated two thousand five hundred dollars cash by a
third party for the creation and dissemination of this content.
This material does not represent an investment solicitation.
Certain statements contained herein constitute “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements may include, without
limitation, statements with respect to the Company’s plans and
objectives, projections, expectations and intentions. These
forward-looking statements are based on current expectations,
estimates and projections about the Company’s industry,
management’s beliefs and certain assumptions made by
management.
The above communication, the attachments and external Internet
links provided are intended for informational purposes only and are
not to be interpreted by the recipient as a solicitation to
participate in securities offerings. Investments referenced
may not be suitable for all investors and may not be permissible in
certain jurisdictions.
Spotlight Growth and its affiliates, officers, directors, and
employees may have bought or sold or may buy or sell shares in the
companies discussed herein, which may be acquired prior, during or
after the publication of these marketing materials. Spotlight
Growth, its affiliates, officers, directors, and employees may sell
the stock of said companies at any time and may profit in the event
those shares rise in value. For more information on our
disclosures, please
visit: http://spotlightgrowth.com/index.php/disclosures/
Matt Rego
9165257147
mrego@spotlightgrowth.com
Marizyme (QB) (USOTC:MRZM)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Marizyme (QB) (USOTC:MRZM)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024